January 9, 2017 8:18am

 

JPMorgan conference kicks off in San Francisco

Try getting in and when and if you do, the “pushers” will shove you through the “listening “rooms

350 companies will be presenting and attendees; what might be revealed, if any substance about the prospects for 2017…

 

I answer one question; in which company should investors put, keep and commit their money!

 

Who is in today’s headlights – two (2) equities, are they a BUY or a SELL?

 

Miss me, it’s time to become a 2017 subscriber – free reads are over! So, what do I really think ...

 

I write in every line that investors need to avoid risks as if I were the first to be hurt if I am wrong!

 

 

I am right more often than not and investors have always been able to count on ME for return on investment (ROI); start thinking return on speculation!

 

 

BUY: I am “holding” my water for the JPM conference to illuminate or “cast a shadow” on the fewer “faithful”?

Sell:  CLBS and KITE

 

Indexes and ETFs: The IWM (-0.33%) is DOWN; the XBI (+1.64%) is UP is while the XLV and IBB are NOT indicating

Dow futures are DOWN -0.13% and NASDAQ futures are UP +0.03%

 

U.S. stock index futures pointed to a lower open on Monday as traders eyed a potential breakthrough the elusive 20,000 mark for the Dow and focused on earnings.

European bourses were lower in morning trade, bucking the trend seen across other global markets, as investors focused on fresh data from the euro zone and volatility in oil markets.

Asian markets were higher, following the Dow coming within inches of hitting the 20,000 mark during last Friday's session.

 

Data docket: consumer credit for November released at 3 p.m. ET.

 

 

The stem, cell, gene and regenerative therapy (SCG&RT) sector closed NEGATIVE on Friday and Thursday, POSITIVE on Wednesday and Tuesday following a holiday last Monday.

The SCG&RT sector’s record after the last 5 days (of 43 covered companies):

·         Friday closed NEGATIVE with 23 decliners, 18 advancers and 3 flats;

·         Thursday closed NEGATIVE with 25 decliners, 15 advancers and 3 flats;

·         Wednesday closed POSITIVE  with 6 decliners, 34 advancers and 3 flats;

·         Tuesday closed POSITIVE with 12 decliners, 30 advancers and 1 flat;

·         Last Monday was a holiday;

 

 

Remembering Friday’s closing bell newsletter, “Friday, we saw the usual drip after a number of up days; the past two down sessions after two up closes have done nothing to improve the fortunes of the SCG&RT’s stocks.”

  • Reiterating, “The sector remains under the “thumb” of sentiment due to the prospect of some management’s believability causing a rotation into other stronger companies or just outright sales as well as sensitive, daily trading downdrafts.”

Investors are going to bail on the stem, cell, gene and regenerative therapy stocks.

  • How many are presenting at JPMorgan as the lesser meetings gather the rest – few!

For 18 years, I attended as a loyal Hambrect&Quist alumni but, the conference has become a Japanese train station event.

 

I will let the “posers” and the "flat-liners" fill-in for me!

 

 

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades? 

Watch list:

·         The iShares Nasdaq Biotechnology (IBB) closed  Friday up +0.78% and is NOT indicating in Monday’s pre-market;

·         The SPDR S&P Biotech ETF (XBI) closed Friday up +1.41% and is UP +1.64% in Monday’s after-market;

·         The Health Care Select Sector SPDR ETF (XLV) closed up +0.28% Friday and is NOT indicating in Monday’s pre-market;

·         The iShares Russell 2000 (IWM) closed down -0.37% on Friday and is DOWN -0.33% in Monday’s pre-market

 

                                                                                   

Companies in my headlights – short, sweet and some sour:

  • As I stated above, we need to reset expectation for 2017 –thus, I am “holding” my water for the JPM conference to illuminate or “cast a shadow” on the fewer “faithful”?

Some s elected events will make some of the acquirers happy but, those lft standing will be very … ALONE …

 

Caladrius Biosciences (CLBS0 closed DOWN -$0.05 to $3.28. A private placement investor stiffs company for $6 M – wonder why? $6 million from a single investor in a targeted to be received in Q4/16 has yet to be received. CLBS has continued to remain in dialogue with this investor and has received assurances that the transfer of capital will be … forthcoming? – SELL;

Kite Pharma (KITE) closed UP another +$1.56 to $51.24 following Thursday’s $49.88 (+$0.70) after Wednesday’s $48.98 (+$3.03) after Tuesday’s $45.95 (+$1.11) and last Friday’s $44.84. There is $6.40 of upside in the pot; I’d sell into the strength– Maintaining SELL;

                                                                                                                                                         

 

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Henry’s comments are for informational purposes only and are not a substitute for personalized advice. Consult your advisor about what is best for you.